Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T18:47:10.100Z.
Calculation as of: 2026-10-06T18:47:10.100Z.
Quote observation: 2026-10-06T18:43:32.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c94dd91991be4d96189a92c60ca8c4546f597a2bd6811cd9696b114923955f60
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
DataMEDS AI, Inc.
Market Cap
$8.47M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| DataMEDS AI, Inc. (MEDS) | $8.47M | N/A |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.38M | N/A |
| HeartSciences Inc. (HSCS)vs › | $8.10M | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $8.07M | N/A |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $8.90M | N/A |
| Jasper Therapeutics, Inc. (JSPR)vs › | $8.99M | N/A |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.86M | N/A |
| Traws Pharma, Inc. (TRAW)vs › | $7.93M | N/A |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.86M | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.75M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
